ValuEngine downgraded shares of Idera Pharmaceuticals (NASDAQ:IDRA) from a sell rating to a strong sell rating in a research report report published on Friday morning.
A number of other brokerages also recently issued reports on IDRA. Zacks Investment Research downgraded Idera Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, January 17th. BidaskClub upgraded Idera Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Tuesday, January 16th. Finally, HC Wainwright set a $4.00 price target on Idera Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Idera Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $4.20.
Shares of IDRA opened at $1.64 on Friday. The stock has a market capitalization of $354.25, a PE ratio of -3.90 and a beta of 2.35. Idera Pharmaceuticals has a 52 week low of $1.32 and a 52 week high of $2.87.
In other Idera Pharmaceuticals news, major shareholder Invest Corp Pillar sold 200,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $2.40, for a total transaction of $480,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 12.42% of the company’s stock.
A number of hedge funds have recently modified their holdings of IDRA. BlackRock Inc. raised its holdings in shares of Idera Pharmaceuticals by 38.1% during the fourth quarter. BlackRock Inc. now owns 9,005,243 shares of the biotechnology company’s stock valued at $19,000,000 after acquiring an additional 2,486,098 shares during the last quarter. Bain Capital Public Equity Management LLC acquired a new position in shares of Idera Pharmaceuticals during the fourth quarter valued at approximately $4,816,000. Millennium Management LLC raised its holdings in shares of Idera Pharmaceuticals by 135.9% during the fourth quarter. Millennium Management LLC now owns 3,854,325 shares of the biotechnology company’s stock valued at $8,133,000 after acquiring an additional 2,220,674 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Idera Pharmaceuticals by 45.4% during the third quarter. JPMorgan Chase & Co. now owns 3,359,875 shares of the biotechnology company’s stock valued at $7,526,000 after acquiring an additional 1,048,475 shares during the last quarter. Finally, Vident Investment Advisory LLC acquired a new position in shares of Idera Pharmaceuticals during the fourth quarter valued at approximately $1,351,000. Institutional investors own 36.55% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Idera Pharmaceuticals (IDRA) Cut to Strong Sell at ValuEngine” was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3342585/idera-pharmaceuticals-idra-cut-to-strong-sell-at-valuengine.html.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.